Xiaoyan Jiang, Qianyuan Zhang, Ziying Zheng, Zhiyong Shen, Qiong Luo
{"title":"肝细胞癌癌症特异性死亡分层的潜在分类分析衍生分类。","authors":"Xiaoyan Jiang, Qianyuan Zhang, Ziying Zheng, Zhiyong Shen, Qiong Luo","doi":"10.1002/ijc.35399","DOIUrl":null,"url":null,"abstract":"<p>The heterogeneity in prognostic survival and treatment response of hepatocellular carcinoma (HCC) limits the accurate assessment of HCC-specific mortality. This study aimed to identify potential HCC subtypes through latent class analysis (LCA) to improve HCC-specific mortality prediction and optimize treatment recommendations. We analyzed data from 7746 HCC patients in the Surveillance, Epidemiology, and End Results (SEER) databases, incorporating demographic and clinicopathological information and applying LCA to identify HCC subtypes. Prognostic survival and treatment response across different HCC subtypes were evaluated utilizing Cox proportional hazards regression and competing risks models. The classification was externally validated with data from 6791 patients. Four HCC subtypes (LCAC1–LCAC4) were determined. Compared with LCAC1, both LCAC2 (HR = 1.887, <i>p</i> < .001) and LCAC4 (HR = 1.317, <i>p</i> < .001) were associated with significantly shorter overall survival. LCAC2 had the highest HCC-specific mortality (HR: 2.395, <i>p</i> < .001), followed by LCAC4 (HR: 1.531, <i>p</i> < .001), and LCAC3 (HR: 1.424, <i>p</i> < .001). LCAC3 was associated with the lowest risk of non-HCC-specific mortality (HR: 0.613, <i>p</i> < .001). Surgical treatment, particularly preoperative systemic therapy, significantly improved survival across all HCC subtypes, whereas chemotherapy and radiotherapy had limited efficacy in LCAC1 and LCAC3 patients. External validation corroborated these findings. This study provides a classification system that differentiates HCC-specific mortality, facilitating accurate survival stratification and treatment recommendations, and provides valuable insight for clinical decision-making.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"157 2","pages":"325-335"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma\",\"authors\":\"Xiaoyan Jiang, Qianyuan Zhang, Ziying Zheng, Zhiyong Shen, Qiong Luo\",\"doi\":\"10.1002/ijc.35399\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The heterogeneity in prognostic survival and treatment response of hepatocellular carcinoma (HCC) limits the accurate assessment of HCC-specific mortality. This study aimed to identify potential HCC subtypes through latent class analysis (LCA) to improve HCC-specific mortality prediction and optimize treatment recommendations. We analyzed data from 7746 HCC patients in the Surveillance, Epidemiology, and End Results (SEER) databases, incorporating demographic and clinicopathological information and applying LCA to identify HCC subtypes. Prognostic survival and treatment response across different HCC subtypes were evaluated utilizing Cox proportional hazards regression and competing risks models. The classification was externally validated with data from 6791 patients. Four HCC subtypes (LCAC1–LCAC4) were determined. Compared with LCAC1, both LCAC2 (HR = 1.887, <i>p</i> < .001) and LCAC4 (HR = 1.317, <i>p</i> < .001) were associated with significantly shorter overall survival. LCAC2 had the highest HCC-specific mortality (HR: 2.395, <i>p</i> < .001), followed by LCAC4 (HR: 1.531, <i>p</i> < .001), and LCAC3 (HR: 1.424, <i>p</i> < .001). LCAC3 was associated with the lowest risk of non-HCC-specific mortality (HR: 0.613, <i>p</i> < .001). Surgical treatment, particularly preoperative systemic therapy, significantly improved survival across all HCC subtypes, whereas chemotherapy and radiotherapy had limited efficacy in LCAC1 and LCAC3 patients. External validation corroborated these findings. This study provides a classification system that differentiates HCC-specific mortality, facilitating accurate survival stratification and treatment recommendations, and provides valuable insight for clinical decision-making.</p>\",\"PeriodicalId\":180,\"journal\":{\"name\":\"International Journal of Cancer\",\"volume\":\"157 2\",\"pages\":\"325-335\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-03-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35399\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35399","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
肝细胞癌(HCC)预后生存和治疗反应的异质性限制了HCC特异性死亡率的准确评估。本研究旨在通过潜在分类分析(LCA)识别潜在的HCC亚型,以提高HCC特异性死亡率预测和优化治疗建议。我们分析了来自监测、流行病学和最终结果(SEER)数据库的7746例HCC患者的数据,结合人口统计学和临床病理信息,并应用LCA来识别HCC亚型。使用Cox比例风险回归和竞争风险模型评估不同HCC亚型的预后生存和治疗反应。该分类通过6791例患者的数据进行外部验证。四种HCC亚型(LCAC1-LCAC4)被确定。与LCAC1相比,LCAC2 (HR = 1.887, p < .001)和LCAC4 (HR = 1.317, p < .001)的总生存期均显著缩短。LCAC2的hcc特异性死亡率最高(HR: 2.395, p
Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma
The heterogeneity in prognostic survival and treatment response of hepatocellular carcinoma (HCC) limits the accurate assessment of HCC-specific mortality. This study aimed to identify potential HCC subtypes through latent class analysis (LCA) to improve HCC-specific mortality prediction and optimize treatment recommendations. We analyzed data from 7746 HCC patients in the Surveillance, Epidemiology, and End Results (SEER) databases, incorporating demographic and clinicopathological information and applying LCA to identify HCC subtypes. Prognostic survival and treatment response across different HCC subtypes were evaluated utilizing Cox proportional hazards regression and competing risks models. The classification was externally validated with data from 6791 patients. Four HCC subtypes (LCAC1–LCAC4) were determined. Compared with LCAC1, both LCAC2 (HR = 1.887, p < .001) and LCAC4 (HR = 1.317, p < .001) were associated with significantly shorter overall survival. LCAC2 had the highest HCC-specific mortality (HR: 2.395, p < .001), followed by LCAC4 (HR: 1.531, p < .001), and LCAC3 (HR: 1.424, p < .001). LCAC3 was associated with the lowest risk of non-HCC-specific mortality (HR: 0.613, p < .001). Surgical treatment, particularly preoperative systemic therapy, significantly improved survival across all HCC subtypes, whereas chemotherapy and radiotherapy had limited efficacy in LCAC1 and LCAC3 patients. External validation corroborated these findings. This study provides a classification system that differentiates HCC-specific mortality, facilitating accurate survival stratification and treatment recommendations, and provides valuable insight for clinical decision-making.
期刊介绍:
The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories:
-Cancer Epidemiology-
Cancer Genetics and Epigenetics-
Infectious Causes of Cancer-
Innovative Tools and Methods-
Molecular Cancer Biology-
Tumor Immunology and Microenvironment-
Tumor Markers and Signatures-
Cancer Therapy and Prevention